NCT02939326View on ClinicalTrials.gov

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 12, 2017

Study Completion Date

July 12, 2017

Conditions

Glabellar Frown Lines (GL)

Interventions

DRUG

EB-001 injection

DRUG

Placebo injection

Trial Locations (2)

92663

Steve Yoelin, MD Medical Associates, INC., Newport Beach

94538

Center For Dermatology Clinical Research, Inc., Fremont

All Listed Sponsors

lead

Bonti, Inc.

INDUSTRY

NCT02939326 - Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines | Biotech Hunter | Biotech Hunter